

CLUSTER · CYCLE

# Immune cytopenias cluster - Q2 2026 briefing

Rolling cluster: chronic primary ITP, AIHA, warm + cold antibody disease. Quarter window: Apr-Jun 2026.  
Snapshot locked 2026-06-30. Anchor sources unchanged from Q1 2026. Reviewer + revision history  
embedded in audit slide.

EHA 2026 (LIVE)

EMA CHMP

FDA

CT.GOV DELTA

PUBMED Q2

CADENCE

# Rolling Tier 2 quality. Quarterly cycles. Change log discipline.

Anchor source set frozen across cycles unless the change is logged in slide 06. Every claim from a prior cycle is restated or explicitly retired. No silent drift.

CADENCE

**Quarterly**

CYCLE WINDOW

**90 days**

PRICE BAND

**EUR 6-12K / mo**

SNAPSHOT

**2026-06-30**

STALENESS RULE

**90 days**

REVIEWER PASS

**Per cycle**

EMA EPAR

FDA

CT.GOV

EHA / ASH

PUBMED

## CHANGE LOG

# What moved this quarter. What was retired. What stays.

Three movement tags: New (first appearance), Updated (anchor refreshed), Retired (claim no longer survives). Every row cites the trigger source.

CLAIM OR ASSET	MOVEMENT	TIER	TRIGGER SOURCE
Rilzabrutinib (BTK) LUNA 3 positive readout - primary endpoint met in cITP	NEW	SOURCED	EHA 2026 late-breaker LB-2407
Efgartigimod label - SC formulation approval expanded to adult cITP (EU)	UPDATED	SOURCED	EMA CHMP Jun 2026 opinion
Romiplostim SC durable response week-24 = 79% (RAISE legacy)	UPDATED	SOURCED	RAISE extension RWE Q2 2026
Fostamatinib (SYK) salvage positioning vs combination regimens	RETIRED	HEDGED	Editorial - retired pending head-to-head data
AIHA - sutimlimab uptake plateau in cold agglutinin disease (EU 5)	NEW	INFERRED	Q2 2026 EU 5 IQVIA pull

## WHAT THIS QUARTER CHANGES

# Three sequencing implications tied to verified change-log entries.

Implications, not raw data. Each recommendation cites the change-log row that triggered it. Recommendation tier matches source tier.

- **ciTP MSL messaging - 30 days:** Brief field on rilzabrutinib LUNA 3 readout (slide 03 row 1). Position vs TPO-RA SC durability + FcRn fast onset, not as replacement. **SOURCED**
- **FcRn access posture - 60 days:** Update payer dossier for efgartigimod SC EU label extension (slide 03 row 2). Site-of-care argument shifts from IV-infusion to SC-home. **SOURCED**
- **AIHA scan trigger - watch:** Sutimlimab cold-AD uptake plateau (slide 03 row 5) suggests competitive dynamics opening. Probe scope for dedicated AIHA T1 next cycle. **INFERRED**
- **Retired claim watch:** Fostamatinib salvage row retired pending head-to-head data. Track FIT-2 extension publication; if RWE arrives, reopen.

WHAT OPENED. WHAT CLOSED.

## Probe register - Q2 closes two, opens three.

Probes survive across cycles until resolved or retired. Every probe carries an owner + cycle opened + resolution criterion.

### Closed Q2 - Probe P-2026-014

"Does rilzabrutinib hit primary endpoint?" Resolved YES via EHA 2026 LB-2407. Folded into change log row 1.

### Closed Q2 - Probe P-2026-009

"Will efgartigimod SC formulation extend EU label?" Resolved YES via CHMP opinion Jun 2026. Folded into change log row 2.

### Opened Q2 - Probe P-2026-021

"Does BTK class fit before or after FcRn in second-line cITP?" No head-to-head data yet. Probe stays open through Q3.

### Opened Q2 - Probe P-2026-022

"Sutimlimab uptake plateau - access barrier or saturation?" EU 5 RWE pull next cycle. Add MSL field probes.

- **Watch Q3:** ASH 2026 late-breaker submission window closes Aug 14. Track cITP and AIHA abstracts.

## HOW THIS CYCLE WAS BUILT

# Quarter-to-quarter audit traceable. No silent drift.

Anchor source set frozen from Q1 2026. Change log slide propagates to next cycle as carry-forward. Gate A: deep-research verification. Gate B: LLM-council adversarial review. Peer reviewer pass per cycle.

## Cycle deltas vs Q1 2026

- Anchor sources unchanged (EMA + FDA + CT.gov + PubMed + EHA + ASH)
- Added: EU 5 IQVIA Q2 pull (sutimlimab AIHA uptake probe)
- Snapshot date moved 2026-03-31 -> 2026-06-30
- Reviewer rotation: [Reviewer A] -> [Reviewer B] this cycle
- One claim retired with reason recorded (fostamatinib row)

## Carry-forward to Q3 2026

- P-2026-021 (BTK sequencing) - stays open
- P-2026-022 (sutimlimab plateau) - stays open
- ASH 2026 late-breaker window watch
- Romiplostim RAISE-extension RWE - update if new dataset
- Reviewer rotation: [Reviewer B] -> [Reviewer C]

Cycle ID: [DLV-RET-2026-Q2](#) · Prior cycle: [DLV-RET-2026-Q1](#) · Intake schema: [v1.1.0](#)